These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 20515941)

  • 21. Pazopanib combined with radiation: in vivo model of interaction.
    Meredith RF; Raisch KP; Bonner JA; Buchsbaum DJ; Grizzle WE; Li Y; Spencer SA
    Cancer Biother Radiopharm; 2014 Aug; 29(6):247-50. PubMed ID: 24945464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
    Nikolinakos PG; Altorki N; Yankelevitz D; Tran HT; Yan S; Rajagopalan D; Bordogna W; Ottesen LH; Heymach JV
    Cancer Res; 2010 Mar; 70(6):2171-9. PubMed ID: 20215520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
    Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
    Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deeper penetration into tumor tissues and enhanced in vivo antitumor activity of liposomal paclitaxel by pretreatment with angiogenesis inhibitor SU5416.
    Yoshizawa Y; Ogawara K; Fushimi A; Abe S; Ishikawa K; Araki T; Molema G; Kimura T; Higaki K
    Mol Pharm; 2012 Dec; 9(12):3486-94. PubMed ID: 23134499
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
    Paesler J; Gehrke I; Gandhirajan RK; Filipovich A; Hertweck M; Erdfelder F; Uhrmacher S; Poll-Wolbeck SJ; Hallek M; Kreuzer KA
    Clin Cancer Res; 2010 Jul; 16(13):3390-8. PubMed ID: 20570929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.
    Podar K; Tonon G; Sattler M; Tai YT; Legouill S; Yasui H; Ishitsuka K; Kumar S; Kumar R; Pandite LN; Hideshima T; Chauhan D; Anderson KC
    Proc Natl Acad Sci U S A; 2006 Dec; 103(51):19478-83. PubMed ID: 17164332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.
    Kim SJ; Jung KH; Son MK; Park JH; Yan HH; Fang Z; Kang YW; Han B; Lim JH; Hong SS
    Cancer Lett; 2017 Sep; 403():339-353. PubMed ID: 28688971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.
    Inglis DJ; Lavranos TC; Beaumont DM; Leske AF; Brown CK; Hall AJ; Kremmidiotis G
    Cancer Biol Ther; 2014; 15(11):1552-60. PubMed ID: 25482941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of pazopanib on tumour angiogenesis and in the management of cancers: A review.
    Chellappan DK; Chellian J; Ng ZY; Sim YJ; Theng CW; Ling J; Wong M; Foo JH; Yang GJ; Hang LY; Nathan S; Singh Y; Gupta G
    Biomed Pharmacother; 2017 Dec; 96():768-781. PubMed ID: 29054093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment with EGCG in NSCLC leads to decreasing interstitial fluid pressure and hypoxia to improve chemotherapy efficacy through rebalance of Ang-1 and Ang-2.
    Deng PB; Hu CP; Xiong Z; Yang HP; Li YY
    Chin J Nat Med; 2013 May; 11(3):245-53. PubMed ID: 23725836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.
    Bianconi M; Faloppi L; Loretelli C; Zizzi A; Giampieri R; Bittoni A; Andrikou K; Del Prete M; Burattini L; Montironi R; Scartozzi M; Cascinu S
    Oncotarget; 2016 Jun; 7(25):37599-37607. PubMed ID: 27175586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
    Kernt M; Thiele S; Neubauer AS; Koenig S; Hirneiss C; Haritoglou C; Ulbig MW; Kampik A
    Retina; 2012 Sep; 32(8):1652-63. PubMed ID: 22466477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
    Stacchiotti S; Tortoreto M; Baldi GG; Grignani G; Toss A; Badalamenti G; Cominetti D; Morosi C; Dei Tos AP; Festinese F; Fumagalli E; Provenzano S; Gronchi A; Pennacchioli E; Negri T; Dagrada GP; Spagnuolo RD; Pilotti S; Casali PG; Zaffaroni N
    Eur J Cancer; 2014 Nov; 50(17):3021-8. PubMed ID: 25269954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Normalization of the vasculature for treatment of cancer and other diseases.
    Goel S; Duda DG; Xu L; Munn LL; Boucher Y; Fukumura D; Jain RK
    Physiol Rev; 2011 Jul; 91(3):1071-121. PubMed ID: 21742796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy.
    Shen G; Li Y; Du T; Shi G; Dai L; Chen X; Zheng R; Li W; Su X; Zhang S; Wei Y; Yang S; Deng H
    Neoplasma; 2012; 59(5):486-93. PubMed ID: 22668017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.
    Sloan B; Scheinfeld NS
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1324-35. PubMed ID: 19037839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
    Wang D; Tang F; Wang S; Jiang Z; Zhang L
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model.
    Hylander BL; Sen A; Beachy SH; Pitoniak R; Ullas S; Gibbs JF; Qiu J; Prey JD; Fetterly GJ; Repasky EA
    J Control Release; 2015 Nov; 217():160-9. PubMed ID: 26342663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pazopanib inhibits the activation of PDGFRβ-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells.
    Gril B; Palmieri D; Qian Y; Anwar T; Liewehr DJ; Steinberg SM; Andreu Z; Masana D; Fernández P; Steeg PS; Vidal-Vanaclocha F
    Am J Pathol; 2013 Jun; 182(6):2368-79. PubMed ID: 23583652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.